{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.29","pValueComment":"Two-sided significance level = 0.05","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8"},{"groupId":"OG001","value":"21.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"733"},{"groupId":"OG001","value":"728"}],"units":"Participants"}],"description":"Rate of acute 2+ grade genitourinary(GU)/gastrointestinal(GI) toxicity graded by Common Toxicity Criteria (CTC) version 2.0","groups":[{"description":"70.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.","id":"OG000","title":"70.2 Gy"},{"description":"79.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.","id":"OG001","title":"79.2 Gy"}],"paramType":"NUMBER","populationDescription":"Eligible patients with acute adverse event data who did not withdraw consent.","reportingStatus":"POSTED","timeFrame":"From the start of treatment to 90 days. Analysis occurs at the same time as the primary endpoint","title":"Grade 2 or Greater Genitourinary or Gastrointestinal Toxicity","type":"SECONDARY","unitOfMeasure":"percentage of participants"}